Phase 4 Obesity Trial, Recruiting (NCT06396416)

Phase 4 Obesity Trial, Recruiting NCT06396416 Sponsor: Western University, Canada Condition: Obesity

Printed from Voxsanity (voxsanity.com.au) — NCT06396416 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Obesity

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults who are 18 years of age or older
People with a BMI of 35 kg/m² or higher
People who have at least a 10% chance of developing kidney failure requiring dialysis or transplant within 2 years, or who are already receiving dialysis

Who may not be able to join:

People who have a medical reason why they cannot take a type of medication called a GLP-1 receptor agonist — this includes a history of pancreatitis (inflammation of the pancreas), a personal or family history of a specific type of thyroid cancer called medullary thyroid cancer, or a known allergic reaction to this type of medication
People with Type 1 diabetes
People for whom drug coverage does not make semaglutide (the medication used in this trial) accessible through their insurance or benefits scheme (confirm with trial site)
People who are pregnant, breastfeeding, or planning to become pregnant
People who are currently enrolled in another clinical trial involving a GLP-1 receptor agonist medication, or who are planning to join one

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Kristin K Clemens, MD, MSc, St. Joseph's Health Care London

Phone: 519-646-6100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06396416

Sponsor: Western University, Canada

Phase: Phase 4

Status: Recruiting

Condition: Obesity

Trial contact: 519-646-6100

More information: https://clinicaltrials.gov/study/NCT06396416

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults who are 18 years of age or older
People with a BMI of 35 kg/m² or higher
People who have at least a 10% chance of developing kidney failure requiring dialysis or transplant within 2 years, or who are already receiving dialysis

Who may not be able to join:

People who have a medical reason why they cannot take a type of medication called a GLP-1 receptor agonist — this includes a history of pancreatitis (inflammation of the pancreas), a personal or family history of a specific type of thyroid cancer called medullary thyroid cancer, or a known allergic reaction to this type of medication
People with Type 1 diabetes
People for whom drug coverage does not make semaglutide (the medication used in this trial) accessible through their insurance or benefits scheme (confirm with trial site)
People who are pregnant, breastfeeding, or planning to become pregnant
People who are currently enrolled in another clinical trial involving a GLP-1 receptor agonist medication, or who are planning to join one

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Western University, Canada

Registry

ClinicalTrials.gov

Start date

26 September 2024

Est. completion

30 September 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Feasibility of Recruitment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov